论文部分内容阅读
目的观察吡膀胱癌术后应用柔比星膀胱内灌注效果。方法选取2012年3月-2015年3月我院收治的膀胱癌术后患者102例。以数字法随即分为观察组和对照组各51例。观察组患者给予吡柔比星膀胱内灌注治疗,对照组患者接受常规手术治疗。所有患者均进行为期2年的随访,对比两组治疗效果。结果观察组不良反应发生率为56.86%(29/51),低于对照组的82.35%(42/51),差异有统计学意义(P<0.05);观察组患者1年、2年复发率分别为11.76%(6/51)、21.57%(11/51),均显著低于对照组的39.22%(20/51)、60.78%(31/51),差异均有统计学意义(均P<0.05)。结论膀胱癌术后应用吡柔比星膀胱内灌注在效果显著,可明显降低不良反应发生率及复发率。
Objective To observe the intravesical instillation of epirubicin in patients with bladder cancer after operation. Methods From March 2012 to March 2015, 102 cases of postoperative bladder cancer admitted to our hospital were selected. The digital method was divided into observation group and control group of 51 cases. Patients in the observation group were treated with intravesical perfusion of pirarubicin, and patients in the control group received conventional surgery. All patients were followed up for 2 years, comparing the two groups of treatment. Results The incidence of adverse reactions in the observation group was 56.86% (29/51), which was lower than that in the control group (82.35%, 42/51) (P <0.05). The 1-year and 2-year recurrence rates (11.76%) and 21.57% (11/51) respectively, which were significantly lower than that of the control group (39.22%, 20/51) and 60.78% (31/51) <0.05). Conclusion Intravesical instillation of pirarubicin after bladder cancer operation has a significant effect, which can significantly reduce the incidence of adverse reactions and recurrence rate.